Insights Into Non-small Cell Lung Cancer (NSCLC) 2022
Perspectives of community physicians from across the US on the drivers in treatment decisions in the management of lung cancer
Northeast – August 20, 2022
Faculty Chair
Narjust Duma, MD
Dana-Farber Cancer Institute, Boston, MA, USA
Midwest – September 16, 2022
Faculty Chair
Corey Langer, MD
University of Pennsylvania, Philadelphia, PA, USA
Northwest – November 18, 2022
Faculty Chair
Sushil Bhardwaj, MD
Good Samaritan Hospital, Suffern, NY, USA
More Information
- Philadelphia, PA
- New Jersey, Pennsylvania, Massachusetts, Maine, Connecticut, New York
More Information
- Chicago, IL
- Illinois, Iowa, Nebraska, North Dakota, South Dakota, Wisconsin, Michigan, Indiana, Ohio
More Information
- Seattle, WA
- Northern California, Oregon, Washington, Idaho, Montana, Wyoming
REPORT SNAPSHOT
- A moderated roundtable discussion focusing on the management and current use of treatment options for EGFR-mutant NSCLC in the community setting
- Disease state and data presentations were developed in conjunction with a national or regional oncology expert
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Data collection was accomplished through use of audience response system questioning and moderated discussion
- The group of advisors comprised 10–15 medical oncologists representative of each region
